This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

About SomavertAbout Somavert

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

About SomavertEfficacySafety profileDosingTumour impact
Support & ResourcesSupport & Resources

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Supporting your patientsUsing SomavertStarter kitsHomecareAcroQoL Survey Healthcare professional and patient materialsVideosMaterialsGot any questions?Endocrine HelplineContact us
ReimbursementFunding and Reimbursement

Learn about funding and reimbursement for England, Scotland, Wales and Northern Ireland

Funding and ReimbursementNHS England BlueteqWales, Scotland & NI

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

TitleSomavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.
EfficacySomavert normalises IGF-1 in a unique way1Somavert mechanism of action

Somavert works on cell surfaces around the body, directly targeting and blocking growth hormone receptors to inhibit IGF-I production with a high predictibility1-3

Somavert can help achieve high rates of IGF-I normalisation1,3,4Somavert IGF-1 normalisation rates at 12 weeks4

Study design: 12-week, randomised, double-blind study of three different doses of pegvisomant (10mg, 15mg, and 20mg) and placebo, given subcutaneously daily, in 112 patients with acromegaly. All patients had previously been treated with surgery, radiation therapy and/or medical therapies. 4

Somavert normalised serum IGF-1 levels in 97% (87 of 90) of patients with appropriate dose titration and close patient follow up3

Baseline and lowest values of individual serum IGF-1 concentrations achieved in 90 patients treated for 12 months or more with daily injections.3

The shaded area represents age adjusted normal range for IGF-1

Study design: Prospective, open-label, 18-month, multicentre extension study that assessed the effects of Somavert in 160 patents with acromegaly treated for an everage of 425 days. 3

*Van der Lely 20013: 87/90 patients taking pegvisomant for 12 months or more.

100/108  (92.6%) of patients with available IGF-1 data had a normal IGF-1 concentration at any visit during pegvisomant treatment. 2/100 patients with normalised IGF-1 were administered doses of >30mg/day5.

The maximum licensed dose of Somavert should not exceed 30mg per day.  Please refer to the Summary of Product Characteristics before prescribing Somavert1.

Somavert’s tumour-independent mechanism of action may explain how it can achieve IGF-1 normalisation rates of up to 97% when appropriately titrated (n=87/90)

Somavert symptom scores reduction at 6 months6

Study Design: Observational multicentre surveillance study using the Patients-assessed Acromegaly Symptoms Questionnaire (PASQ) to evaluate signs and symptoms of acromegaly. Answers are scored based on 0 (no symptoms) to 8 (severe, incapacitating symptoms), or 0 (best possible health status) to 10 (worst possible health status).6

*Schreiber 20176:Of the 229 patients in the study, 94.1% of patients received doses between 10 and 30mg/day.  Five patients had 10mg every second day; 6 patients recieved more than 30mg/day. ​​​​​​​6​​​​​​

The maximum recommended dose of Somavert is 30mg/day.  Please refer to the Summary of Product Characteristics before prescribing'.1

Patients on Somavert report significant reductions versus baseline in soft tissue swelling, headache, joint pain and general physical condition, and total signs and symptoms score‡1,6

Total signs and symptoms score reduction observed at 12 weeks (p<0.05, n=112).

Contact Us

To find out more about supporting your patients or to order starter kits.

Contact UsLoading
Somavert dosing

Help find your patient's personal optimum by titrating doses 

Learn more Loading

References

Somavert Summary of Product Characteristics. Great Britain available here. Northern Ireland available here Sherlock M, et al. Medical therapy in acromegaly. Nat Rev Endocrinol 2011;7:291–300.Van der Lely AJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;24;358(9295):1754–9.TrainerPJ, et al. Treatment of Acromegaly with the growth hormone -receptor antagonist pegvisomant. N Engl J Med 2000; 342(16) :1171-7Pfizer Data on file: PP-SOM-GBR-1104Schreiber I, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156:75–82.
PP-SOM-GBR-1226. June 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​